Immune checkpoints inhibitors in metastatic squamous cell carcinoma of the vulva

Future Oncol. 2021 Aug;17(24):3133-3135. doi: 10.2217/fon-2021-0610. Epub 2021 Jul 2.

Authors

Tarek Assi^{1

2}, Joseph Kattan³, Ahmad Othman², Fadi Farhat²

Affiliations

¹ Department of Hematology & Oncology, Faculty of Medicine, Saint-Joseph University, Beirut, Lebanon.
² Department of Hematology & Oncology, Hammoud Hospital University Medical Centre, Saida 652, Lebanon.
³ Department of Hematology & Oncology, Hotel-Dieu de France University Hospital, Faculty of Medicine, Saint Joseph University, Beirut, Lebanon.

PMID: 34213372
DOI: 10.2217/fon-2021-0610

No abstract available

Keywords: cancer; checkpoint inhibitors; gynecological tumors; immune therapy; vulvar cancer.

Publication types

Editorial

MeSH terms

Antibodies, Monoclonal, Humanized / therapeutic use
Antineoplastic Agents, Immunological / therapeutic use
B7-H1 Antigen / metabolism
Carcinoma, Squamous Cell / drug therapy*
Carcinoma, Squamous Cell / metabolism
Carcinoma, Squamous Cell / secondary
Female
Humans
Immune Checkpoint Inhibitors / therapeutic use*
Nivolumab / therapeutic use
Vulvar Neoplasms / drug therapy*
Vulvar Neoplasms / metabolism
Vulvar Neoplasms / pathology

Substances

Antibodies, Monoclonal, Humanized
Antineoplastic Agents, Immunological
B7-H1 Antigen
CD274 protein, human
Immune Checkpoint Inhibitors
Nivolumab
pembrolizumab